Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Jairia Dela Cruz, 5 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
5 days ago
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.

OnabotulinumtoxinA benefits patients with chronic migraine regardless of response status

Elaine Soliven
22 Aug 2019

Treatment with onabotulinumtoxinA significantly improves headache-related outcomes in patients with chronic migraine (CM) regardless of their response status, according to a study presented at AHS 2019.

The researchers conducted a pooled analysis of data from the phase III PREEMPT* clinical programme comprising a 24-week double-blind phase (two treatment cycles) and a 32-week open-label phase (three treatment cycles).  

A total of 1,384 patients with CM were involved in the study and were stratified, based on their response to treatment, into two subgroups: responders** and nonresponders***. All patients were randomly assigned to receive either onabotulinumtoxinA (n=688, 308 responders and 380 nonresponders) or placebo (n=696, 238 responders and 458 nonresponders) for 24 weeks. HIT-6+ and MSQ++ scores were used to assess the impact of migraine on daily functioning. [AHS 2019, abstract P14]

Among nonresponders, those treated with onabotulinumtoxinA had a significantly greater reduction in the number of moderate/severe headache days from baseline than those who received placebo (p<0.02).

At 24 weeks, onabotulinumtoxinA-treated nonresponders were less affected by migraine, as shown by greater improvements in the HIT-6 scores from baseline, compared with the placebo-treated nonresponders (-2.3 vs -0.8; p<0.001).

Greater improvements were also seen across all domains in the MSQ score, namely the restrictive (8.8 vs 2.9; p<0.001), preventive (6.0 vs 1.8; p<0.001), and emotional domains (8.5 vs 2.8; p<0.001), among nonresponders treated with onabotulinumtoxinA compared with placebo.

In addition, a significant between-treatment difference was already evident among nonresponders who received onabotulinumtoxinA compared with placebo at weeks 4 (p<0.001 for HIT-6 score) and 12 (p<0.02 for MSQ score), which was sustained through 24 weeks.

The differences in HIT-6 and MSQ scores were also evident at weeks 8 (p<0.02) and 12 (p<0.05), respectively, which were also sustained at 24 weeks among responders treated with onabotulinumtoxinA than placebo.

“The above results support a treatment benefit of onabotulinumtoxinA in [patients with] CM at 24 weeks that may not be fully captured by the observed reduction in headache days,” said the researchers.  

The findings are consistent with another study showing that patients treated with onabotulinumtoxinA demonstrated at least a 50 percent improvement in migraine burden even before starting another treatment, said the researchers, who highlighted that “onabotulinumtoxinA injections are a clinically approved therapy for the treatment of CM.” [AHS 2019, abstract P09]  

“OnabotulinumtoxinA treatment was associated with significantly greater improvements than placebo in headache severity, headache-related impact, and quality of life in both headache-day responders and nonresponders as typically defined solely by an arbitrary and binary 50 percent cut-off [≥50 percent reduction in headache days],” the researchers added.

 

*PREEMPT: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy

**Responders: Defined as ≥50 percent reduction in headache days from baseline

***Nonresponders: Defined as <50 percent reduction in headache days from baseline

+HIT-6: 6-domain Headache Impact Test

++MSQ: Migraine-Specific Quality of Life Questionnaire

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Jairia Dela Cruz, 5 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
5 days ago
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.